‘Reverse patent troll’ holsters his club as IPRs continue to even out

When we last met Kyle Bass back in November, the hard-charging hedge-fund tycoon on a mission to stymie what he considered unfair patent practices by large pharmaceutical companies had just scored a pair of rare, and perhaps unexpected, victories.